CVRx, Inc. (CVRX) Tops Q2 EPS by 2c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- AMD shares fall amid AI chip sector selloff
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
CVRx Reports Second Quarter 2023 Financial and Operating Results
July 25, 2023 4:15 PM EDTMINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (CVRx), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the second quarter of 2023.
Recent Highlights
Total revenue for the second quarter of 2023 was $9.5 million, an increase of 89% over prior year quarterU.S. Heart Failure (HF) revenue for the second quarter of 2023 was... More


